Clinical Trial Detail

NCT ID NCT03395847
Title A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

gastroesophageal junction adenocarcinoma

Therapies

Pembrolizumab + Ramucirumab

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.